The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | G | Genito urinary system and sex hormones | |
| 2 | G03 | Sex hormones and modulators of the genital system | |
| 3 | G03D | Progestogens | |
| 4 | G03DB | Pregnadien derivatives |
| Code | Title | |
|---|---|---|
| G03DB01 | Dydrogesterone | |
| G03DB02 | Megestrol | |
| G03DB03 | Medrogestone | |
| G03DB04 | Nomegestrol | |
| G03DB05 | Demegestone | |
| G03DB06 | Chlormadinone | |
| G03DB07 | Promegestone | |
| G03DB08 | Dienogest |
| Active Ingredient | Description | |
|---|---|---|
| Chlormadinone |
|
|
| Dienogest |
Dienogest is a nortestosterone derivative with no androgenic but rather an antiandrogenic activity of approximately one third of that of cyproterone acetate. Dienogest binds to the progesterone receptor of the human uterus with only 10% of the relative affinity of progesterone. |
|
| Dehydroprogesterone |
Dydrogesterone is an orally-active progestogen having an activity comparable to parenterally administered progesterone. |
|
| Medrogestone |
|
|
| Megestrol |
Megestrol possesses pharmacological properties similar to those of natural progesterone. Megestrol acetate is a potent progestogen that exerts significant anti-oestrogenic effects. It has no androgenic or oestrogenic properties. |
|
| Nomegestrol |
|
| Title | Information Source | Document Type | |
|---|---|---|---|
| DUPHASTON Film-coated tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| ROVULUM Film-coated tablet | Health Products Regulatory Authority (ZA) | MPI, Generic | |
| VISANNE Tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| ZAFRILLA Tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC |
